Skip to main content
OpenTrials
Completed

NCT Number: NCT03469921

Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Malignant Haemopathies Acute Leukemia Hemic and Lymphatic Diseases Hodgkin Disease Hodgkin Lymphoma Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Non-Hodgkin Lymphoma

Age range

15 year–30 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Institut Paoli Calmettes

Marseille, Bouches Du Rhone, 13009, France

About this study

The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016.

Exclusion criteria

  • Not applicable

Treatment and study plan

administered therapeutic regimens

Drug

administered therapeutic regimens

Primary outcomes

  1. Global Survival

    Time frame: 15 years

    delay between the date of diagnosis and the date of the latest news

  2. Survival without event

    Time frame: 15 years

    delay between the date of diagnosis and an event (relapse, death, lost of follow-up)

  3. Progression-free survival

    Time frame: 15 years

    defined as the delay between the date of diagnosis and the date of relapse or death.

Secondary outcomes

  1. Epidemiological distribution by pathology compared to the adult population over 30 years

    Time frame: 1 day

    Epidemiological distribution by pathology compared to the adult population over 30 years

  2. Descriptive analysis of the characteristics of the disease at diagnosis by pathology

    Time frame: 15 years

    Descriptive analysis of the characteristics of the disease at diagnosis by pathology

  3. Descriptive analysis of treatments by pathology

    Time frame: 15 years

    Descriptive analysis of treatments by pathology

  4. Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

    Time frame: 15 years

    Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

  5. Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

    Time frame: 15 years

    Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

  6. Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

    Time frame: 15 years

    Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

  7. Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology.

    Time frame: 15 years

    Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology.

Sponsors and collaborators

Lead sponsor

Institut Paoli-Calmettes

Other

Registry information

Acronym: HEMAJA

Important dates

Study start
2000
Primary completion
2016
Study completion
2016
First posted
Mar 19, 2018
Registry last updated
Mar 19, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.